Search

Galectin Therapeutics Inc

Closed

SectorHealthcare

3.96 2.59

Overview

Share price change

24h

Current

Min

3.5300000000000002

Max

3.94

Key metrics

By Trading Economics

Income

-4.1M

-9.1M

EPS

-0.14

Employees

9

EBITDA

2.2M

-827K

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+198.91% upside

Dividends

By Acuity

Next Earnings

13 Nov 2026

Market Stats

By TradingEconomics

Market Cap

39M

354M

Previous open

1.37

Previous close

3.96

News Sentiment

By Acuity

50%

50%

150 / 340 Healthcare

Galectin Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

24 Aug 2026, 23:01 UTC

Shares of Galectin Therapeutics Inc. are lower in after-market trading, with notable volatility and a decline since Monday's close.

21 Aug 2026, 19:16 UTC

Galectin Therapeutics Inc shares are higher today, maintaining a position above the 20-day moving average and near the upper end of their one-month range.

20 Aug 2026, 20:06 UTC

Galectin Therapeutics Inc. shares are lower today, continuing a decline since Wednesday. The price remains above its 20-day moving average.

18 Aug 2026, 19:56 UTC

Galectin Therapeutics Inc. shares are higher today, advancing since Monday's close despite earlier pulling back from session lows. The stock remains above its 20-day moving average.

17 Aug 2026, 19:56 UTC

Galectin Therapeutics Inc. shares are trading higher, recovering from an earlier low and positioned above the 20-day moving average. No specific news was identified.

14 Aug 2026, 19:21 UTC

News

Galectin Therapeutics reports a net loss of $9.2 million for Q2, missing estimates, contributing to a decline in shares during the session.

13 Aug 2026, 20:02 UTC

Galectin Therapeutics Inc shares are higher during Thursday's session, reflecting strong trading activity and unusually high market volume, despite lacking specific company news.

12 Aug 2026, 19:42 UTC

Galectin Therapeutics Inc shares are rising Wednesday amid high trading volume, maintaining an upward trend since Tuesday's close despite pulling back from earlier session highs.

11 Aug 2026, 19:56 UTC

Galectin Therapeutics Inc shares are lower today amid routine fluctuations and no specific news. The stock is near the lower end of its one-month trading range.

10 Aug 2026, 20:02 UTC

Galectin Therapeutics Inc shares are lower today, reflecting a significant decline since Friday amid high trading volume and cautious investor sentiment following a weak jobs report.

8 Aug 2026, 00:01 UTC

Galectin Therapeutics Inc shares are higher in after-market hours, reflecting strong buying activity. The stock has recovered from an early session low.

7 Aug 2026, 23:01 UTC

Galectin Therapeutics Inc shares are higher in after-market hours, recovering from earlier losses amid favorable broader market conditions and a declining unemployment rate.

6 Aug 2026, 22:06 UTC

Galectin Therapeutics Inc shares are lower in after-market trading, continuing a trend below their 20-day moving average amid a significant decline since last month.

5 Aug 2026, 23:02 UTC

Galectin Therapeutics Inc shares are higher in after-market trading, despite no specific news driving the movement. The stock showed significant volatility during the session.

4 Aug 2026, 20:03 UTC

News

Galectin Therapeutics announced a $105.8 million debt-to-equity conversion but shares are lower today after an early peak. Trading volume is unusually high.

3 Aug 2026, 19:46 UTC

Galectin Therapeutics Inc is higher today, continuing an upward trend since Friday's close, despite pulling back from a session high. No specific news was identified.

31 Jul 2026, 21:51 UTC

Galectin Therapeutics Inc is lower in after-market trading, influenced by broader market trends. The asset has faced three consecutive sessions of declines.

30 Jul 2026, 20:10 UTC

Galectin Therapeutics Inc is lower today, breaking a trend of higher daily closes. Increased market volume accompanies the decline amid broader market volatility.

29 Jul 2026, 18:58 UTC

Galectin Therapeutics Inc shares are higher today, continuing an upward trend since Tuesday's close. The stock remains below its 20-day moving average.

28 Jul 2026, 17:46 UTC

Galectin Therapeutics Inc shares are lower today, continuing a decline since Monday's close, amid broader market caution following significant drops in Asian indices.

27 Jul 2026, 16:32 UTC

Galectin Therapeutics Inc shares are lower today, reflecting a notable decline since Friday. The stock has seen unusually high trading volume amid broader market sentiment.

24 Jul 2026, 20:02 UTC

Galectin Therapeutics Inc is lower today, marking its ninth consecutive session of declines. The stock remains below its 20-day moving average.

22 Jul 2026, 19:01 UTC

Galectin Therapeutics Inc. shares are trading lower, following a peak earlier in the session. High trading volume indicates increased investor activity.

21 Jul 2026, 17:16 UTC

Galectin Therapeutics Inc. shares are lower today, continuing a five-session decline and trading significantly below the 20-day moving average. No specific news was identified.

20 Jul 2026, 20:06 UTC

Galectin Therapeutics Inc shares are lower today, continuing a trend of five consecutive daily declines amid broader market volatility linked to geopolitical tensions.

Peer Comparison

Price change

Galectin Therapeutics Inc Forecast

Price Target

By TipRanks

198.91% upside

12 Months Forecast

Average 11 USD  198.91%

High 11 USD

Low 11 USD

Based on 1 Wall Street analysts offering 12 month price targets forGalectin Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Sentiment

By Acuity

150 / 340 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.
help-icon Live chat